Introduction {#Sec1}
============

Extended spectrum β-lactamases (ESBL) are enzymes capable of hydrolyzing penicillins, broad-spectrum cephalosporins, and monobactams \[[@CR1]\]. ESBL-based infections have been noted to result in increased morbidity and mortality. These infections increase cost of care if inappropriate therapy, defined as non-susceptibility of pathogen to therapy by laboratory criteria, is administered \[[@CR2]\]. At present, the Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) do not recommend routine screening for ESBLs or subsequent phenotypic confirmation testing that had been advocated previously \[[@CR3], [@CR4]\]. While this approach has been supported in the clinical practice setting by the introduction of reduced breakpoints for many beta-lactams \[[@CR5]\], it may be of value, particularly when evaluating novel therapies, to understand the potency of various agents against ESBL producers. However, if one utilizes ESBL classification with aztreonam (ATM), ceftriaxone (CRO), or ceftazidime (CAZ) minimum inhibitory concentrations (MIC) as a simple screen, without phenotypic confirmation via the clavulanate test, this approach may include other resistant genotypes (i.e., carbapenemase producers) that may not accurately predict the clinical utility of therapeutic agents under consideration \[[@CR6]\].

Phenotypic screening tests to detect resistance mechanisms such as carbapenemase production or AmpC expression are available and can be used. While molecular testing would yield the most definite results, it is also cost prohibitive and unavailable to most clinical microbiological laboratories. In this study, we tested the recently US Food and Drug Administration (FDA)-approved compound, ceftolozane/tazobactam (C/T), which has demonstrated in vitro activity against some ESBL organisms \[[@CR7]\]. The purpose of this study was to compare the impact of MIC-based screening versus confirmatory testing of ESBLs on the susceptibility profile of C/T versus selected antimicrobials.

Methods {#Sec2}
=======

In this study, 44 US hospitals collected non-duplicate, non-urine *Escherichia coli* (*n* = 1306) and *Klebsiella pneumoniae* (*n* = 1205) over the period of June 2013 and October 2014. Participating sites identified the organisms using their established method and then transferred each isolate to trypticase soy agar slants for shipping. Isolates were transferred onto trypticase soy agar plates containing 5% sheep blood at the central processing laboratory (Center for Anti-Infective Research and Development, Hartford Hospital, Hartford Hospital, Hartford, CT, USA) for MIC determination using broth microdilution as described by CLSI \[[@CR5]\]. MICs were determined for C/T, cefepime (FEP), CRO, CAZ, ciprofloxacin (CIP), ATM, ertapenem (ETP), piperacillin/tazobactam (TZP), meropenem (MEM), and tobramycin (TOB) against this collection of 2511 contemporary clinical Enterobacteriaceae isolates. MIC trays were prepared using the Biomek 3000 (Beckman Instruments, Inc., Fullerton, CA, USA) and frozen at −80 °C until use. C/T was provided by Cubist Pharmaceuticals, while all others antibiotics were purchased from Sigma-Aldrich (St. Louis, MO, USA). *E. coli* 25922 and *Pseudomonas aeruginosa* 27853 were utilized as quality control strains as recommended by CLSI.

CLSI states that the initial MIC-based ESBL screening for *E. coli* and *K. pneumoniae* should be performed by evaluating the MIC profile of one of the following drugs: cefpodoxime 4 µg/mL, CAZ 1 µg/mL, ATM 1 µg/mL, or cefotaxime 1 µg/mL. It is noted that the use of more than one of these agents will improve detection of ESBLs. We defined a positive ESBL screen as having an MIC of ≥1 µg/mL to 2 of the following: ATM, CRO, or CAZ. Subsequent CLSI defined, phenotypic, ESBL confirmation studies were undertaken using CAZ and cefotaxime with and without clavulanate \[[@CR8]\]. Probable carbapenemase-producing organisms were excluded based on ETP (≥1 µg/mL) or MEM (≥2 µg/mL) susceptibility profiles. While molecular-based confirmation of these enzymes would have been definitive, methodologies readily available to the clinical microbiology laboratory were utilized. Percent susceptibility (%S) was based on CLSI breakpoints \[[@CR3]\]. Recently, C/T has been approved in the US and susceptibility interpretative criteria have now been provided by the FDA of ≤2 µg/mL for the Enterobacteriaceae \[[@CR7]\].

This surveillance program was reviewed by the institutional review board (IRB) at the coordinating center, Hartford Hospital. Since all samples were collected as part of routine medical care and no interventions were undertaken as a result of this testing, informed consent was deemed unnecessary by the IRB.

Results {#Sec3}
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Four-hundred and forty-two (18%) isolates \[*E. coli* (*n* = 231), *K. pneumoniae* (*n* = 211)\] screened positive for ESBL production based on MIC-based criteria. Of these, 274 (62%) isolates \[*E. coli* (*n* = 146), *K. pneumoniae* (*n* = 128)\] were phenotypically confirmed positive for ESBL production. With further exclusion of the 28 (10%) isolates \[*E. coli* (*n* = 13), *K. pneumoniae* (*n* = 14)\] that demonstrated carbapenem non-susceptible, a left shift in the MIC distribution (i.e., enhanced potency) against phenotypically confirmed ESBL was noted for C/T, ETP, TZP, and MEM (Table [1](#Tab1){ref-type="table"}). Figure [1](#Fig1){ref-type="fig"} highlights these screening- and confirmation-based observations for C/T and TZP. Improvements in %S between 8% and 17% were noted for confirmed versus screened-positive ESBL isolates for C/T, ETP, TZP, and MEM. (Table [1](#Tab1){ref-type="table"}) Overall, %S of the other β-lactams, TOB and CIP, was poor against phenotypically confirmed ESBLs. Comparing the MIC~90~ values for all ESBL MIC-based screen-positive versus phenotypically confirmed positive, we observed a reduction of twofold for C/T, sixfold for ETP, and eightfold for MEM (Table [2](#Tab2){ref-type="table"}).Table 1Percent susceptibility of all agents against MIC-based screen-positive (Screen +) and phenotypically confirmed (Confirmed +) ESBL *Escherichia* *coli* and *Klebsiella* *pneumoniae* isolatesPercent susceptibility for antimicrobialsC/TFEPCROCAZCIPATMETPTZPMEMTOBAll Screen + (*n* = 442)64211018231674537945 Confirmed + (*n* = 274)7582914691619342 Confirmed +, carbapenem NS removed (*n* = 246)829291371006710042*E. coli* Screen + (*n* = 231)79291324272386699054 Confirmed + (*n* = 146)889310101096759847 Confirmed +, carbapenem NS removed (*n* = 139)91941110101007810047*K. pneumoniae* Screen + (*n* = 211)471251118962366534 Confirmed + (*n* = 128)6171718282468835 Confirmed +, carbapenem NS removed (*n* = 107)717171621005210036*ATM* aztreonam, *CAZ* ceftazidime, *CIP* ciprofloxacin, *CRO* ceftriaxone, *C/T* ceftolozane/tazobactam, *ETP* ertapenem, ESBL extended spectrum β-lactamase, *FEP* cefepime, *MEM* meropenem, *MIC* minimum inhibitory concentration, *NS* non-susceptible, *TOB* tobramycin, *TZP* piperacillin/tazobactamFig. 1The MIC distribution of C/T and TZP for the MIC-based screen-positive isolates (Screen +), phenotypically confirmed positive (Confirmed +) and Confirmed + with carbapenem NS isolates removed (Confirmed +, no carbapenem NS) of all Enterobacteriaceae. *C/T* ceftolozane/tazobactam, *MIC* minimum inhibitory concentration, *NS* non-susceptible, *TZP* piperacillin/tazobactamTable 2MIC~90~ (µg/mL) of all agents against MIC-based screen-positive (Screen +) and phenotypically confirmed (Confirmed +) *Escherichia* *coli* and *Klebsiella* *pneumoniae* isolatesMIC~90~ (µg/mL) for antimicrobialsC/TFEPCROCAZCIPATMETPTZPMEMTOBAll Screen + (*n* = 442)12812812812832128325123264 Confirmed + (*n* = 274)32128128128321280.55120.12564 Confirmed +, carbapenem NS removed (*n* = 246)212812812832640.125640.06464*ATM* aztreonam, *CAZ* ceftazidime, *CIP* ciprofloxacin, *CRO* ceftriaxone, *C/T* ceftolozane/tazobactam, *ETP* ertapenem, ESBL extended spectrum β-lactamase, *FEP* cefepime, *MEM* meropenem, *MIC* minimum inhibitory concentration, *NS* non-susceptible, *TOB* tobramycin, *TZP* piperacillin/tazobactam

Conclusion {#Sec4}
==========

After confirmatory ESBL testing using the clavulanate test, 38% of strains identified as potential ESBL producers using a simple MIC screen were excluded. For agents with potential activity against ESBLs such as C/T, TZP, ETP, and MEM, reduced susceptibility was noted when only considering MIC screen positivity. The reason for this discordance is that carbapenemase producers, AmpC, and other types of resistance would not be differentiated by MIC-based screen testing alone. As such, although MIC screening selects for resistant organisms, inclusion of these other genotypes may falsely under-predict the potency of several antibiotics against ESBL producers and if such a method is used during published surveillance studies, it may limit applicability of these data to geographic areas not plagued with carbapenemase producers. For this reason, in scenarios, such as the clinical laboratory, when molecular testing is not available, clavulanate-based phenotypic confirmatory testing is recommended to better evaluate empiric therapy options against ESBL.
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